<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="discussion" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="allenpress-id">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0050169</article-id><article-id pub-id-type="publisher-id">07-PLME-PF-0994R2</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Policy Forum</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Pediatrics and Child Health</subject>
          <subject>Public Health and Epidemiology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Malaria</subject>
          <subject>Infectious Diseases</subject>
          <subject>Medicine in Developing Countries</subject>
          <subject>Epidemiology</subject>
          <subject>Public Health</subject>
        </subj-group>
      </article-categories><title-group><article-title>Assessing Antimalarial Efficacy in a Time of Change to Artemisinin-Based
          Combination Therapies: The Role of Médecins Sans Frontières</article-title><alt-title alt-title-type="running-head">Policy Forum</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Guthmann</surname>
            <given-names>Jean-Paul</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Checchi</surname>
            <given-names>Francesco</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>van den Broek</surname>
            <given-names>Ingrid</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Balkan</surname>
            <given-names>Suna</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>van Herp</surname>
            <given-names>Michel</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Comte</surname>
            <given-names>Eric</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bernal</surname>
            <given-names>Oscar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kindermans</surname>
            <given-names>Jean-Marie</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Venis</surname>
            <given-names>Sarah</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Legros</surname>
            <given-names>Dominique</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Guerin</surname>
            <given-names>Philippe J</given-names>
          </name>
        </contrib>
      </contrib-group><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail:<email xlink:type="simple">jp.guthmann@invs.sante.fr</email></corresp>
        <fn fn-type="con">
          <p> J-PG co-ordinated the project, compiled the studies, wrote the plan of analysis,
            analysed the data, and wrote the paper. FC had a crucial role in the analysis and
            interpretation of results and gave significant input in the writing of the paper. IvdB,
            SB, MvH, EC, OB, and J-MK compiled data from their MSF section and contributed in data
            interpretation. SV participated in the analysis and interpretation of part of the data
            and had a crucial role in paper writing. DL had an important role in the conception,
            analysis, and interpretation of several individual studies and had an important
            intellectual contribution to the overall intervention, to which he gave important
            epidemiological input. PJG contributed in the conception of the project, in the
            interpretation of results, and in the writing of the paper. All authors participated
            intellectually in this project and in the writing of the paper.</p>
        </fn>
        <fn fn-type="current-aff" id="n3">
          <p>Jean-Paul Guthmann, Francesco Checchi, Ingrid van den Broek, Dominique Legros, and
            Philippe J. Guerin are with Epicentre, Paris, France. Jean-Paul Guthmann is also with
            the Departement de Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice,
            France. Francesco Checchi is also with the Department of Infectious and Tropical
            Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Ingrid
            van den Broek and Sarah Venis are with Medecins Sans Frontieres, London, United Kingdom.
            Ingrid van den Broek is also with Medecins Sans Frontieres, Amsterdam, The Netherlands,
            and the Centre for Infectious Disease Control, National Institute of Public Health and
            the Environment, Bilthoven, The Netherlands. Suna Balkan is with Medecins Sans
            Frontieres, Paris, France. Michel van Herp and Jean-Marie Kindermans are with Medecins
            Sans Frontieres, Brussels, Belgium. Eric Comte is with Medecins Sans Frontieres, Geneva,
            Switzerland. Oscar Bernal is with Medecins Sans Frontieres, Barcelona, Spain. Dominique
            Legros is also with Disease Control in Emergencies, Department of Epidemic and Pandemic
            Alert and Response, World Health Organization, Geneva, Switzerland.</p>
        </fn>
      <fn fn-type="conflict" id="n2">
        <p> The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>8</month>
        <year>2008</year>
      </pub-date><pub-date pub-type="epub">
        <day>5</day>
        <month>8</month>
        <year>2008</year>
      </pub-date><volume>5</volume><issue>8</issue><elocation-id>e169</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2008</copyright-year><copyright-holder> Guthmann et al</copyright-holder><license><license-p>This is an open-access article distributed under the
        terms of the Creative Commons Attribution License, which permits unrestricted use,
        distribution, and reproduction in any medium, provided the original author and source are
        credited.</license-p></license></permissions><abstract abstract-type="toc">
        <p>Jean-Paul Guthmann and colleagues describe the output of MSF's work in antimalarial
          efficacy assessment during the last decade.</p>
      </abstract><funding-group><funding-statement> Individual studies and the present desk-based analysis were financed by the different
          operational sections of MSF, who gave authorisation to compile the existing data in one
          single analysis for publication. The authors received no specific funding for this
          article.</funding-statement></funding-group><counts>
        <page-count count="9"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Guthmann J-P, Checchi F, van den Broek I, Balkan S, van Herp M, et al. (2008)
            Assessing antimalarial efficacy in a time of change to artemisinin-based combination
            therapies: The role of Medecins Sans Frontieres. PLoS Med 5(8): e169. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0050169" xlink:type="simple">10.1371/journal.pmed.0050169</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>During the 1990s, high levels of <named-content content-type="genus-species" xlink:type="simple">Plasmodium
          falciparum</named-content> (<named-content content-type="genus-species" xlink:type="simple">Pf</named-content>) resistance to common antimalarials were reported from malaria-endemic
        countries, raising questions about the efficacy of chloroquine (CQ), then the mainstay of
        antimalarial treatment. Drug resistance was considered a prime contributing factor to
        increased malaria mortality and morbidity across Africa [<xref ref-type="bibr" rid="pmed-0050169-b001">1</xref>,<xref ref-type="bibr" rid="pmed-0050169-b002">2</xref>]. The natural successor to CQ, sulfadoxine-pyrimethamine (SP), had a
        short therapeutic lifespan [<xref ref-type="bibr" rid="pmed-0050169-b003">3</xref>], and the choice of an effective first-line regimen emerged as a key
        issue in <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> malaria control.
        Artemisinin-based combination therapy (ACT), adopted in southeast Asia since the early
        1990s, appeared to be the best available option [<xref ref-type="bibr" rid="pmed-0050169-b003">3</xref>].</p>
      <boxed-text id="pmed-0050169-box001" position="float">
        <sec>
          <title>Summary Points</title>
          <list list-type="bullet">
            <list-item>
              <p>More than 12,000 patients were enrolled in 43 efficacy studies in 18 countries of
                Asia and Africa between 1996 and 2004, accounting for one fourth of the overall
                research output in these countries.</p>
            </list-item>
            <list-item>
              <p>This has provided extensive evidence on the efficacy of most drug regimens
                currently in use for uncomplicated malaria, which was often used for treatment
                policy changes by the concerned countries.</p>
            </list-item>
            <list-item>
              <p>The greatest contribution was in conflict-affected countries of sub-Saharan Africa,
                where studies represent the vast majority of available data and where
                “traditional” academic research institutions were not or barely
                represented.</p>
            </list-item>
            <list-item>
              <p>The vast majority of the studies were published in peer-reviewed journals, which
                shows that research performed in difficult settings can be of a high enough standard
                to ensure publication and to be useful in policy change.</p>
            </list-item>
            <list-item>
              <p>This work demonstrates the potential role of non-governmental agencies in
                collecting the necessary evidence to stimulate and inform policy change in
                international health.</p>
            </list-item>
          </list>
        </sec>
      </boxed-text>
      <p>Médecins Sans Frontières (Doctors Without Borders, or MSF) is a
        humanitarian medical aid organisation, dedicated to providing assistance to populations who
        lack access to health care. In the 1990s, antimalarial resistance was emergent in most
        countries where MSF was operating, but scientific evidence of this resistance was often
        lacking, and CQ or SP were still recommended by national malaria control programmes. Faced
        with a lack of data and the reluctance of international technical advisors and donors to
        review treatment strategies, MSF initiated in vivo studies to document the situation in its
        programme locations. While the primary aim was optimising treatment strategies for MSF
        patients, results were often used to formulate national policy change. Studies followed
        World Health Organization (WHO) recommendations [<xref ref-type="bibr" rid="pmed-0050169-b004">4</xref>,<xref ref-type="bibr" rid="pmed-0050169-b005">5</xref>], were usually conducted in insecure or difficult-to-access sites where
        data were absent, and were generally supported by MSF's epidemiological unit, Epicentre, in
        collaboration with national Ministries of Health, WHO, and other partners.</p>
      <p>Here, we describe the output of MSF's work in antimalarial efficacy assessment during the
        last decade, and place it within the broader context of studies leading to regimen change
        from monotherapies to mostly artemisinin-based combinations during a critical decade in
        malaria control. We also describe challenges and lessons learned whilst carrying out this
        research and discuss its role within antimalarial policy change.</p>
    </sec>
    <sec id="s2">
      <title>Descriptive Analysis of Efficacy Studies</title>
      <sec id="s2a">
        <title>Review methods.</title>
        <p>We identified all malaria in vivo drug efficacy studies for which MSF was the main
          sponsor during 1996–2004, whether published in peer-reviewed journals or
          existing as unpublished reports in MSF operational centres (Brussels, Paris, Amsterdam,
          Barcelona, and Geneva; unpublished reports are available upon request from <email xlink:type="simple">epimail@epicentre.msf.org</email>). Only <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> studies were considered. For every
          study, we compiled country and site, year of completion, treatment group(s) tested, drug
          allocation method, length of post-enrolment follow-up (14 days or less; more than 14 days,
          i.e., at least 28-day follow-up), and failure rate with 95% confidence
          intervals. A treatment group is defined as the regimen tested. Multi-centric studies
          simultaneously evaluating several treatment groups within the same country were treated as
          single studies.</p>
        <p>We calculated the proportion of MSF study treatment groups among all treatment groups
          tested against <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> per country
          during 1996 to 2004 by consulting the Global Malaria Program database (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/resistance.html" xlink:type="simple">http://www.who.int/malaria/resistance.html</ext-link>). We reviewed the WHO Global
          Antimalarial Drug Policy Database (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/treatmentpolicies.html" xlink:type="simple">http://www.who.int/malaria/treatmentpolicies.html</ext-link>) and reference document
            [<xref ref-type="bibr" rid="pmed-0050169-b006">6</xref>] to establish
          the occurrence and timing of changes in treatment policy for uncomplicated malaria. We did
          not consider the introduction of CQ and SP in combination, as this was not a recommended
          option to replace either monotherapy [<xref ref-type="bibr" rid="pmed-0050169-b007">7</xref>]. We compared the new drug policy to findings
          and recommendations of the relevant MSF malaria studies and calculated the proportion of
          countries where recommendations made by MSF were concordant with subsequent national
          decisions regarding policy change.</p>
        <p>To calculate the proportion of MSF papers among all published papers published in
          peer-reviewed journals, we searched PubMed to identify antimalarial studies published
          since 1996 until up to April 2007, performed in the countries in which MSF's studies had
          taken place, and reporting original in vivo efficacy data for treatment of uncomplicated
            <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> malaria in non-pregnant
          populations. Keywords were “malaria” and country of intervention
          (e.g., “Angola”).</p>
      </sec>
      <sec id="s2b">
        <title>Study output.</title>
        <p>Between 1996 and 2004, MSF performed 43 efficacy studies or clinical trials in 18
          countries, of which eight (17%) were in Asia (five countries) and 35
          (83%) in Africa (13 countries) (<xref ref-type="fig" rid="pmed-0050169-g001">Figure 1</xref>). Half of the studies took place in four African countries (21/43,
          49%): Angola (<italic>n</italic> = 5), the Democratic Republic of
          the Congo (DRC, <italic>n</italic> = 6), Uganda (<italic>n</italic>
          = 5), and Sudan (<italic>n</italic> = 5). 12,145 patients were
          enrolled. Most studies (88%) were conducted between 2001 and 2004 and had a
          follow-up of 28 days or more (<italic>n</italic> = 34, 79%) with
          genotypic analysis of presumed failures/parasite recurrences to distinguish recrudescence
          from reinfection (<xref ref-type="fig" rid="pmed-0050169-g002">Figure 2</xref>). Of
          studies with 28-day follow-up, 28/34 (82%) were published in peer-reviewed
          journals, and three out of 34 (9%) had been submitted to peer-reviewed journals
          at the time of writing; conversely, only three out of nine (33%) 14-day studies
          were published (<xref ref-type="table" rid="pmed-0050169-t001">Table 1</xref>).</p>
        <fig id="pmed-0050169-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0050169.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Flow Chart of Sites and Type of MSF <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> Efficacy Studies, 1996–2004</title>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.g001" xlink:type="simple"/>
        </fig>
        <fig id="pmed-0050169-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0050169.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Number of MSF <named-content content-type="genus-species" xlink:type="simple">Pf</named-content>
              Efficacy Studies and Treatment Groups (Monotherapies and ACT) Per Year of Completion,
              1996–2004</title>
            <p>Cells with X represent studies of 14-day follow-up or less; empty cells represent
              studies of 28-day follow-up or more. Mono = monotherapies.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.g002" xlink:type="simple"/>
        </fig>
        <table-wrap content-type="7col" id="pmed-0050169-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0050169.t001</object-id><label>Table 1</label><caption>
            <title>MSF <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> Efficacy
              Studies by Site, Year of Completion, Drug Tested, and Result</title>
          </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.t101" xlink:type="simple"/></table-wrap>
        <table-wrap content-type="7col" id="pmed-0050169-t101" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0050169.t101</object-id><label>Table 1 Continued</label><caption>
            <title>MSF <named-content content-type="genus-species" xlink:type="simple">Pf</named-content> Efficacy
              Studies by Site, Year of Completion, Drug Tested, and Result</title>
          </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.t102" xlink:type="simple"/><!-- <table frame="hsides" rules="groups"><colgroup><col id="tb1col1" align="left"/><col id="tb1col2" align="left"/><col id="tb1col3" align="left"/><col id="tb1col4" align="left"/><col id="tb1col5" align="left"/><col id="tb1col6" align="left"/><col id="tb1col7" align="left"/></colgroup><thead><tr><td><bold>Country</bold></td><td><bold>Site</bold></td><td><bold>Year</bold></td><td><bold>Drug</bold></td><td><bold>Failure Rate (&percnt;)<xref ref-type="fn" rid="nt101"><sup>a</sup></xref></bold></td><td><bold>95&percnt; Confidence Interval (&percnt;)</bold></td><td><bold>Reference<xref ref-type="fn" rid="nt102"><sup>b</sup></xref></bold></td></tr></thead><tbody><tr><td colspan="7"><bold>At least 28-day follow-up: 34 studies</bold></td></tr><tr><td>Myanmar</td><td>Kachin</td><td>1998</td><td>CQ</td><td>79.2</td><td>68.4&ndash;87.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b016">16</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>80.8</td><td>69.9&ndash;89.1</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ</td><td>23.0</td><td>14.0&ndash;34.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ-AS<sub>3</sub></td><td>20.5</td><td>12.0&ndash;31.6</td><td>&nbsp;</td></tr><tr><td>Laos</td><td>Sekong</td><td>2000</td><td>CQ</td><td>39.7</td><td>29.5&ndash;50.7</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b017">17</xref>&rsqb;</td></tr><tr><td>Uganda</td><td>Mbarara</td><td>2000</td><td>SP</td><td>59.3</td><td>51.3&ndash;67.0</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b018">18</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS<sub>1</sub></td><td>54.0</td><td>44.4&ndash;63.3</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS<sub>3</sub></td><td>22.3</td><td>15.3&ndash;30.7</td><td>&nbsp;</td></tr><tr><td>South Sudan</td><td>Kajo Keji</td><td>2001</td><td>CQ</td><td>93.9</td><td>87.3&ndash;97.3</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b019">19</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>69.9</td><td>60.0&ndash;78.3</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>25.2</td><td>17.7&ndash;34.5</td><td>&nbsp;</td></tr><tr><td>Myanmar</td><td>Rakhine</td><td>2001</td><td>MQ<sub>15</sub>-AS1</td><td>5.9</td><td>3.0&ndash;10.3</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b020">20</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>25</sub>-AS<sub>1</sub></td><td>3.6</td><td>1.5&ndash;7.4</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>25</sub>-AS<sub>3unsup</sub></td><td>3.9</td><td>1.7&ndash;8.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>25</sub>-AS<sub>3sup</sub></td><td>0.0</td><td>0.0&ndash;2.1</td><td>&nbsp;</td></tr><tr><td>India</td><td>Assam &amp; Karbi Anglong</td><td>2001</td><td>CQ</td><td>65.9</td><td>48.8&ndash;78.1</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b021">21</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>39.0</td><td>25.3&ndash;54.0</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>15</sub></td><td>4.4</td><td>0.54&ndash;15.1</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>15</sub>-AS</td><td>10.9</td><td>3.6&ndash;23.5</td><td>&nbsp;</td></tr><tr><td>India</td><td>Sonitpur</td><td>2001</td><td>CQ</td><td>95.8</td><td>83.5&ndash;98.7</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b021">21</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>57.1</td><td>42.2&ndash;71.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>15</sub></td><td>7.8</td><td>2.2&ndash;18.9</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ<sub>15</sub>-AS</td><td>1.8</td><td>0.5&ndash;9.9</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Matru</td><td>2001</td><td>CQ</td><td>61.8</td><td>52.1&ndash;70.8</td><td>Bachy C, Epicentre Internal Report 2002</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>22.4</td><td>14.1&ndash;32.7</td><td>&nbsp;</td></tr><tr><td>Bangladesh</td><td>Chittagong</td><td>2002</td><td>Qui-SP</td><td>12.9</td><td>8.1&ndash;17.7</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b022">22</xref>&rsqb;</td></tr><tr><td>Liberia</td><td>Harper</td><td>2002</td><td>CQ</td><td>84.0</td><td>70.9&ndash;92.8</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b023">23</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>69.7</td><td>57.1&ndash;80.4</td><td>&nbsp;</td></tr><tr><td>Liberia</td><td>Harper</td><td>2002</td><td>AQ</td><td>23.5</td><td>14.8&ndash;34.2</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b024">24</xref>&rsqb;</td></tr><tr><td>Zambia</td><td>Maheba</td><td>2002</td><td>SP-AS<sub>sup</sub></td><td>16.4</td><td>9.0&ndash;26.5</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b025">25</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS<sub>unsup</sub></td><td>36.6</td><td>26.2&ndash;47.9</td><td>&nbsp;</td></tr><tr><td>Uganda</td><td>Bundibugyo</td><td>2002</td><td>SP</td><td>37.0</td><td>27.1&ndash;47.7</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b026">26</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>20.6</td><td>11.7&ndash;32.7</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>CQ-SP</td><td>22.8</td><td>14.1&ndash;33.6</td><td>&nbsp;</td></tr><tr><td>Chad</td><td>Bongor</td><td>2002</td><td>CQ</td><td>23.7</td><td>14.7&ndash;34.8</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b027">27</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>16.3</td><td>9.4&ndash;25.5</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>6.4</td><td>2.1&ndash;14.3</td><td>&nbsp;</td></tr><tr><td>Uganda</td><td>Amudat</td><td>2003</td><td>CQ-SP</td><td>52.8</td><td>35.5&ndash;69.6</td><td>Grandesso F, Epicentre Internal Report 2004</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>14.3</td><td>4.0&ndash;32.7</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS</td><td>7.9</td><td>2.6&ndash;17.6</td><td>&nbsp;</td></tr><tr><td>Bangladesh</td><td>Chittagong</td><td>2003</td><td>CQ-SP</td><td>37.6</td><td>48.8&ndash;37.4</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b028">28</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ-AS</td><td>0.9</td><td>0.0&ndash;3.5</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>A-L</td><td>2.9</td><td>0.6&ndash;8.4</td><td>&nbsp;</td></tr><tr><td>South Sudan</td><td>Nuba</td><td>2003</td><td>SP-AS</td><td>8.8</td><td>2.9&ndash;19.3</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b029">29</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>7.3</td><td>2.0&ndash;17.6</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Freetown<xref ref-type="fn" rid="nt103"><sup>c</sup></xref></td><td>2003</td><td>CQ</td><td>67.8</td><td>54.4&ndash;79.4</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b030">30</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>28.0</td><td>16.2&ndash;42.5</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>7.4</td><td>2.1&ndash;17.9</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Kabala</td><td>2003</td><td>CQ</td><td>39.5</td><td>25.0&ndash;55.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b030">30</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>23.2</td><td>13.9&ndash;34.9</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>18.2</td><td>9.8&ndash;29.6</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Kailahun</td><td>2003</td><td>CQ</td><td>78.8</td><td>65.3&ndash;88.9</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b030">30</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>46.1</td><td>35.4&ndash;57.0</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>29.8</td><td>20.3&ndash;40.7</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Makeni</td><td>2003</td><td>CQ</td><td>70.0</td><td>55.4&ndash;82.1</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b030">30</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>24.0</td><td>15.8&ndash;33.7</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>5.4</td><td>1.8&ndash;12.1</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Matru</td><td>2003</td><td>AQ</td><td>13.0</td><td>6.4&ndash;22.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b030">30</xref>&rsqb;</td></tr><tr><td>North Sudan</td><td>Malakal</td><td>2003</td><td>SP-AS</td><td>0.9</td><td>0.0&ndash;4.8</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b031">31</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>1.0</td><td>0.0&ndash;5.6</td><td>&nbsp;</td></tr><tr><td>Angola</td><td>Caala</td><td>2003</td><td>CQ</td><td>83.5</td><td>74.1&ndash;90.5</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b032">32</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>17.3</td><td>10.0&ndash;27.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>25.3</td><td>16.7&ndash;35.8</td><td>&nbsp;</td></tr><tr><td>Angola</td><td>Kuito</td><td>2003</td><td>AQ</td><td>21.6</td><td>14.3&ndash;30.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b032">32</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>38.8</td><td>28.4&ndash;30.6</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>1.2</td><td>0.0&ndash;6.4</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS</td><td>1.2</td><td>0.0&ndash;6.4</td><td>&nbsp;</td></tr><tr><td colspan="7"><bold>At least 28-day follow-up: 34 studies</bold></td></tr><tr><td>South Sudan</td><td>Mapel</td><td>2003</td><td>CQ</td><td>82.7</td><td>71.8&ndash;90.1</td><td>Bachy et al., Epicentre Internal Report 2003</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>15.7</td><td>9.3&ndash;25.1</td><td>&nbsp;</td></tr><tr><td>Chad</td><td>Koumra</td><td>2003</td><td>CQ</td><td>32.9</td><td>22.1&ndash;45.1</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b027">27</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>4.3</td><td>1.2&ndash;10.5</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>2.2</td><td>0.3&ndash;7.6</td><td>&nbsp;</td></tr><tr><td>Cambodia</td><td>Anglong Veng &amp; Kvav</td><td>2003</td><td>Piperaq-DHA</td><td>2.5</td><td>0.7&ndash;6.2</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b033">33</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ-AS</td><td>2.5</td><td>0.7&ndash;6.2</td><td>&nbsp;</td></tr><tr><td>Guinea</td><td>Dabola</td><td>2004</td><td>SP-AS</td><td>1.0</td><td>0.0&ndash;5.5</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b034">34</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>1.0</td><td>0.0&ndash;5.3</td><td>&nbsp;</td></tr><tr><td>DRC</td><td>Kabalo</td><td>2004</td><td>SP</td><td>22.9</td><td>12.0&ndash;37.3</td><td>Bonnet et al., submitted</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS</td><td>0.0</td><td>0.0&ndash;7.3</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>0.0</td><td>0.0&ndash;6.8</td><td>&nbsp;</td></tr><tr><td>DRC</td><td>Shabunda</td><td>2004</td><td>SP-AS</td><td>19.7</td><td>10.9&ndash;31.3</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b035">35</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>6.8</td><td>2.2&ndash;15.1</td><td>&nbsp;</td></tr><tr><td>Congo</td><td>Kindamba</td><td>2004</td><td>AQ-AS</td><td>1.5</td><td>0.0&ndash;8.0</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b036">36</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS</td><td>9.9</td><td>19.3&ndash;4.1</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>A-L</td><td>0.0</td><td>0.0&ndash;5.2</td><td>&nbsp;</td></tr><tr><td>Uganda</td><td>Mbarara</td><td>2004</td><td>A-L<sub>sup</sub></td><td>2.3</td><td>1.0&ndash;4.9</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b037">37</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>A-L<sub>unsup</sub></td><td>2.0</td><td>1.0&ndash;3.5</td><td>&nbsp;</td></tr><tr><td>Angola</td><td>Caala</td><td>2004</td><td>AQ-AS</td><td>0.0</td><td>0.0&ndash;5.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b038">38</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>A-L</td><td>0.0</td><td>0.0&ndash;5.8</td><td>&nbsp;</td></tr><tr><td>Sierra Leone</td><td>Kailahun</td><td>2004</td><td>AQ-AS</td><td>15.5</td><td>9.3&ndash;23.6</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b039">39</xref>&rsqb;</td></tr><tr><td>Mali</td><td>Koumantou</td><td>2004</td><td>CQ</td><td>90.5</td><td>84.8&ndash;96.2</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b040">40</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>7.0</td><td>1.9&ndash;12.1</td><td>&nbsp;</td></tr><tr><td>DRC</td><td>Boende</td><td>2004</td><td>SP</td><td>43.4</td><td>32.2&ndash;55.2</td><td>Bonnet et al., submitted</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>25.8</td><td>16.1&ndash;38.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP-AS</td><td>32.8</td><td>21.6&ndash;46.1</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>19.0</td><td>10.3&ndash;31.8</td><td>&nbsp;</td></tr><tr><td>DRC</td><td>Kilwa</td><td>2004</td><td>SP-AS</td><td>9.8</td><td>3.6&ndash;22.2</td><td>Bonnet et al., submitted</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ-AS</td><td>18.2</td><td>9.5&ndash;31.3</td><td>&nbsp;</td></tr><tr><td>Myanmar</td><td>Rakhine</td><td>2004</td><td>Piperaq-DHA</td><td>0.6</td><td>0.2&ndash;2.5</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b041">41</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>MQ-AS</td><td>0.0</td><td>0.0&ndash;1.2</td><td>&nbsp;</td></tr><tr><td colspan="7"><bold>14-day follow-up: 9 studies</bold></td></tr><tr><td>Angola<xref ref-type="fn" rid="nt104"><sup>d</sup></xref></td><td>Mbanza Congo</td><td>1997</td><td>CQ</td><td>57.2</td><td>50.9&ndash;63.2</td><td>MSF, Internal Report 1997</td></tr><tr><td>Uganda</td><td>Mbarara</td><td>1998</td><td>CQ</td><td>81.1</td><td>68.0&ndash;90.5</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b042">42</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>25.0</td><td>15.0&ndash;37.4</td><td>&nbsp;</td></tr><tr><td>Burundi</td><td>Kayanza</td><td>2001</td><td>CQ</td><td>100.0</td><td>91.8&ndash;100</td><td>Legros D, Dantoine F, Epicentre Report 2001</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>74.8</td><td>65.7&ndash;82.2</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>CQ-SP</td><td>56.9</td><td>46.7&ndash;66.5</td><td>&nbsp;</td></tr><tr><td>Burundi</td><td>Karuzi</td><td>2001</td><td>CQ</td><td>97.8</td><td>86.8&ndash;99.9</td><td>Legros D, Dantoine F, Epicentre Report 2001</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>89.7</td><td>80.8&ndash;94.9</td><td>&nbsp;</td></tr><tr><td>DRC</td><td>Pweto</td><td>2001</td><td>SP</td><td>51.0</td><td>38.4&ndash;63.0</td><td>MSF, Internal Report 2001</td></tr><tr><td>DRC</td><td>Multi-centric</td><td>2001</td><td>CQ</td><td>45.4</td><td>40.1&ndash;50.8</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b043">43</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>7.5</td><td>5.0&ndash;11.0</td><td>&nbsp;</td></tr><tr><td>South Sudan</td><td>Lankien</td><td>2001</td><td>CQ</td><td>11.5</td><td>6.1&ndash;19.3</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0050169-b044">44</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>0.0</td><td>0.0&ndash;3.6</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>AQ</td><td>5.9</td><td>2.2&ndash;12.5</td><td>&nbsp;</td></tr><tr><td>Nigeria</td><td>Bayelsa</td><td>2001</td><td>CQ</td><td>70.5</td><td>61.8&ndash;78.2</td><td>Hardwick et al., MSF Internal Report 2001</td></tr><tr><td>Nigeria</td><td>Bayelsa</td><td>2002</td><td>AQ</td><td>8.6</td><td>4.0&ndash;15.6</td><td>MSF, Internal Report, 2002</td></tr><tr><td>Angola</td><td>Malange</td><td>2002</td><td>CQ</td><td>79.7</td><td>69.2&ndash;87.9</td><td>Prinseberg T, Broeder R, MSF Internal Report</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>SP</td><td>8.6</td><td>3.5&ndash;17.0</td><td>2002</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt101"><p><sup>a</sup>These are usually 28-day PCR corrected failure rates, except in 6 studies: &lsqb;<xref ref-type="bibr" rid="pmed-0050169-b016">16</xref>,<xref ref-type="bibr" rid="pmed-0050169-b020">20</xref>,<xref ref-type="bibr" rid="pmed-0050169-b021">21</xref>,<xref ref-type="bibr" rid="pmed-0050169-b028">28</xref>,<xref ref-type="bibr" rid="pmed-0050169-b031">31</xref>,<xref ref-type="bibr" rid="pmed-0050169-b033">33</xref>&rsqb;, where failure rates are given at day 42 or 63.</p></fn><fn id="nt102"><p><sup>b</sup>Unpublished reports are available upon request from <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:type="simple">epimail@epicentre.msf.org</email>.</p></fn><fn id="nt103"><p><sup>c</sup>Study done by Concern Worldwide/Sierra Leone Ministry of Health/WHO, with MSF Epicentre supervision.</p></fn><fn id="nt104"><p><sup>d</sup>In this study, the follow-up was 7 days.</p></fn><fn><p>A-L, artemether-lumefantrine; AS<sub>1</sub>, artesunate one day; AS<sub>3</sub>. artesunate three days; AS<sub>sup</sub>, artesunate supervised; AS<sub>unsup</sub>, artesunate un-supervised; MQ<sub>15</sub>, mefloquine 15 mg/kg; MQ<sub>25</sub> , mefloquine 25 mg/kg; Piperaq-DHA, piperaquine-dihydroartemisinin; Qui, quinine.</p></fn></table-wrap-foot> --></table-wrap>
        <p>Overall, nine (21%) studies were single arm, whereas 34 (79%) were
          comparative. Of the comparative studies, 22 (65%) were randomised. 117
          treatment groups were investigated, of which 69 (59%) were monotherapies (SP,
            <italic>n</italic> = 27; CQ, <italic>n</italic> = 24; amodiaquine
          [AQ], <italic>n</italic> = 15; mefloquine
          [MQ], <italic>n</italic> = 3) and 48 (41%) were
          combinations. Most combinations (90%) were artemisinin-based (artesunate
          [AS]-SP, <italic>n</italic> = 14; AS-AQ, <italic>n</italic>
          = 12; AS-MQ, <italic>n</italic> = 10, artemether-lumefantrine,
            <italic>n</italic> = 5; dihydroartemisinin-piperaquine, <italic>n</italic>
          = 2); the remaining five were quinine-SP (<italic>n</italic> = 1) or
          CQ-SP (<italic>n</italic> = 4). The number of ACT studies increased over time,
          from one in 1998 to 20 (80% of total) in 2004 (<xref ref-type="fig" rid="pmed-0050169-g002">Figure 2</xref>).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Contribution of MSF Studies to the Evidence for Policy Change</title>
      <p>Within these 18 countries and during 1996–2004, 455 treatment groups were
        investigated, 112 (25%) by MSF (<xref ref-type="table" rid="pmed-0050169-t002">Table 2</xref>). The proportion of study groups investigated by MSF was higher for ACTs
        (46%) than monotherapies (19%), and higher in Africa than in Asia,
        both for monotherapies (23% versus 9%) and ACTs (57% versus
        29%). Recommendations made by MSF were concordant with subsequent national
        decisions regarding policy change in 13/18 (72%) of the countries of intervention
        (Asia: two out of five [40%]; Africa: 11/13
        [84%]).</p>
      <p>Of the 43 MSF studies, 31 (72%) were published in peer-reviewed journals. MSF
        studies accounted for 23% (31/137) of all articles published during this period
        in the 18 countries of intervention (<xref ref-type="table" rid="pmed-0050169-t003">Table
        3</xref>).</p>
      <table-wrap content-type="12col" id="pmed-0050169-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0050169.t002</object-id><label>Table 2</label><caption>
          <title>Number of Studies Performed by MSF Epicentre among Total Studies by Country and
            Drug (Monotherapy, ACT) and Concordance between MSF Recommendations and New Policy
            Subsequently Adopted by the Country</title>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.t002" xlink:type="simple"/><!-- <table frame="hsides" rules="groups"><colgroup><col id="tb2col1" align="left"/><col id="tb2col2" align="left"/><col id="tb2col3" align="left"/><col id="tb2col4" align="left"/><col id="tb2col5" align="left"/><col id="tb2col6" align="left"/><col id="tb2col7" align="left"/><col id="tb2col8" align="left"/><col id="tb2col9" align="left"/><col id="tb2col10" align="left"/><col id="tb2col11" align="left"/><col id="tb2col12" align="left"/></colgroup><thead><tr><td rowspan="3" valign="top"><bold>Country</bold></td><td colspan="6"><bold>MSF&ndash;Epicentre Studies/Total Studies</bold><hr/></td><td rowspan="3" valign="top"><bold>Year(s) of Study</bold></td><td rowspan="3" valign="top"><bold>ACT(s) Recommended by MSF</bold></td><td rowspan="3" valign="top"><bold>Year of Change</bold></td><td rowspan="3" valign="top"><bold>New Policy</bold></td><td rowspan="3" valign="top"><bold>Concordance between MSF Recommendations and New Policy</bold></td></tr><tr><td colspan="2"><bold>Monotherapies</bold><hr/></td><td colspan="2"><bold>ACT</bold><hr/></td><td colspan="2"><bold>Total</bold><hr/></td></tr><tr><td><bold>n/N</bold></td><td><bold>&percnt;</bold></td><td><bold>n/N</bold></td><td><bold>&percnt;</bold></td><td><bold>n/N</bold></td><td><bold>&percnt;</bold></td></tr></thead><tbody><tr><td colspan="12"><bold>Asia</bold></td></tr><tr><td>Bangladesh</td><td>0/4</td><td>0</td><td>2/2</td><td>100</td><td>2/6</td><td>33</td><td>2003</td><td>AS-MQ, A-L</td><td>2004</td><td>A-L</td><td>Yes</td></tr><tr><td>Cambodia</td><td>0/0</td><td>NA</td><td>2/17</td><td>12</td><td>2/17</td><td>12</td><td>2003</td><td>None</td><td>2000</td><td>AS-MQ</td><td>No</td></tr><tr><td>India</td><td>6/40</td><td>15</td><td>2/2</td><td>100</td><td>8/42</td><td>19</td><td>2001</td><td>AS-MQ</td><td>2004</td><td>SP, AS-SP</td><td>No</td></tr><tr><td>Laos</td><td>1/9</td><td>11</td><td>0/4</td><td>0</td><td>1/13</td><td>8</td><td>2000</td><td>None</td><td>2001</td><td>A-L</td><td>No</td></tr><tr><td>Myanmar</td><td>3/54</td><td>5</td><td>7/19</td><td>41</td><td>10/73</td><td>14</td><td>1998, 2001&ndash;04</td><td>AS-MQ</td><td>2002</td><td>AS-MQ, A-L</td><td>Yes</td></tr><tr><td>Total: Asia</td><td>10/107</td><td>9</td><td>13/44</td><td>29</td><td>23/151</td><td>15</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="12"><bold>Africa</bold></td></tr><tr><td>Angola</td><td>8/16</td><td>50</td><td>4/4</td><td>100</td><td>12/20</td><td>60</td><td>1997, 2003&ndash;04</td><td>AS-AQ, A-L</td><td>2004</td><td>A-L</td><td>Yes</td></tr><tr><td>Burundi</td><td>4/8</td><td>50</td><td>0/4</td><td>0</td><td>4/12</td><td>33</td><td>2001</td><td>AS-AQ, A-L</td><td>2003</td><td>AS-AQ</td><td>Yes</td></tr><tr><td>Congo</td><td>0/5</td><td>0</td><td>3/3</td><td>100</td><td>3/8</td><td>37</td><td>2004</td><td>A-L, AS-AQ</td><td>No change</td><td>&nbsp;</td><td>No</td></tr><tr><td>DRC</td><td>6/19</td><td>31</td><td>8/14</td><td>57</td><td>14/33</td><td>42</td><td>2001&ndash;04</td><td>A-L</td><td>2004</td><td>AS-AQ</td><td>No</td></tr><tr><td>Guinea</td><td>0/8</td><td>0</td><td>2/2</td><td>100</td><td>2/10</td><td>20</td><td>2004</td><td>AS-SP, AS-AQ</td><td>2004</td><td>AS-AQ</td><td>Yes</td></tr><tr><td>Mali</td><td>2/22</td><td>9</td><td>0/0</td><td>NA</td><td>2/22</td><td>9</td><td>2004</td><td>AS-SP, AS-AQ, A-L</td><td>2004</td><td>A-L</td><td>Yes</td></tr><tr><td>Nigeria</td><td>2/20</td><td>10</td><td>0/0</td><td>NA</td><td>2/20</td><td>10</td><td>2001&ndash;02</td><td>ACT, no precision</td><td>2004</td><td>A-L</td><td>Yes</td></tr><tr><td>Liberia</td><td>3/3</td><td>100</td><td>0/0</td><td>NA</td><td>3/3</td><td>100</td><td>2002</td><td>AS-AQ</td><td>2004</td><td>AS-AQ</td><td>Yes</td></tr><tr><td>Sierra Leone</td><td>15/17</td><td>88</td><td>1/1</td><td>100</td><td>16/18</td><td>89</td><td>2001&ndash;03&ndash;04</td><td>AS-AQ</td><td>2004</td><td>AS-AQ</td><td>Yes</td></tr><tr><td>Sudan</td><td>8/40</td><td>20</td><td>4/10</td><td>40</td><td>12/50</td><td>24</td><td>2001&ndash;03</td><td>AS-SP, A-L</td><td>2004</td><td>AS-AQ, AS-SP</td><td>Yes</td></tr><tr><td>Chad</td><td>6/7</td><td>86</td><td>0/0</td><td>NA</td><td>6/7</td><td>86</td><td>2002&ndash;03</td><td>AS-AQ</td><td>2004</td><td>AS-AQ</td><td>Yes</td></tr><tr><td>Uganda</td><td>5/48</td><td>10</td><td>6/6</td><td>100</td><td>11/54</td><td>20</td><td>98, 2000&ndash;02&ndash;03&ndash;04</td><td>AS-AQ, AS-SP, A-L</td><td>2004</td><td>A-L</td><td>Yes</td></tr><tr><td>Zambia</td><td>0/39</td><td>0</td><td>2/8</td><td>25</td><td>2/47</td><td>4</td><td>2002</td><td>A-L</td><td>2002</td><td>A-L</td><td>Yes</td></tr><tr><td>Total: Africa</td><td>59/252</td><td>23</td><td>30/52</td><td>57</td><td>89/304</td><td>29</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Total: All</td><td>69/359</td><td>19</td><td>43/96</td><td>46</td><td>112/455</td><td>25</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Countries</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table> --><!-- <table-wrap-foot><fn><p>A-L, artemether-lumefantrine; NA, not applicable.</p></fn></table-wrap-foot> --></table-wrap>
      <table-wrap content-type="3col" id="pmed-0050169-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0050169.t003</object-id><label>Table 3</label><caption>
          <title>Number and Proportion of Articles Published in Peer-Reviewed Journals,
            1996–2007</title>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050169.t003" xlink:type="simple"/><!-- <table frame="hsides" rules="groups"><colgroup><col id="tb3col1" align="left"/><col id="tb3col2" align="left"/><col id="tb3col3" align="left"/></colgroup><thead><tr><td><bold>Country</bold></td><td><bold>Total Articles (<italic>n</italic>)</bold></td><td><bold>MSF Articles (<italic>n</italic>)</bold></td></tr></thead><tbody><tr><td>Angola</td><td>3</td><td>3</td></tr><tr><td>Liberia</td><td>2</td><td>2</td></tr><tr><td>Sierra Leone</td><td>2</td><td>2</td></tr><tr><td>Chad</td><td>2</td><td>2</td></tr><tr><td>Bangladesh</td><td>7</td><td>2</td></tr><tr><td>Burundi</td><td>3</td><td>0</td></tr><tr><td>Uganda</td><td>24</td><td>4</td></tr><tr><td>Sudan</td><td>15</td><td>4</td></tr><tr><td>Myanmar</td><td>5</td><td>3</td></tr><tr><td>Guinea</td><td>1</td><td>1</td></tr><tr><td>DRC</td><td>2</td><td>2</td></tr><tr><td>Cambodia</td><td>5</td><td>1</td></tr><tr><td>India</td><td>15</td><td>1</td></tr><tr><td>Laos</td><td>9</td><td>1</td></tr><tr><td>Congo</td><td>5</td><td>1</td></tr><tr><td>Mali</td><td>4</td><td>1</td></tr><tr><td>Nigeria</td><td>27</td><td>0</td></tr><tr><td>Zambia</td><td>6</td><td>1</td></tr><tr><td><bold>Total</bold></td><td><bold>137</bold></td><td><bold>31 (23&percnt;)</bold></td></tr></tbody></table> --></table-wrap>
      <p>MSF's largest output was in conflict-affected countries of sub-Saharan Africa, including
        Angola, Burundi, Chad, Liberia, Sierra Leone, and southern Sudan, where its studies
        represent the vast majority of available data, and where “traditional”
        academic research institutions were not or barely represented. Overall, MSF's study output
        accounted for one quarter of antimalarial drug efficacy research in 18 countries. Most
        studies were published in peer-reviewed journals.</p>
    </sec>
    <sec id="s4">
      <title>Challenges and Lessons Learned</title>
      <sec id="s4a">
        <title>Generalisability of results obtained in crisis settings.</title>
        <p>With the exception of Sierra Leone, where a national multi-centric study was carried out,
          the MSF studies were not necessarily representative of national trends. Armed conflict,
          forced displacement in Maheba, Zambia and Kailahun, Sierra Leone (potentially leading to
          the introduction of more or less resistant strains), and conflict-induced nutritional
          crises (leading to lower immuno-competence and thus impaired host response) that had
          recently affected many of the study populations (Angola; Burundi; DRC; Lankien, Mapel, and
          Nuba, southern Sudan; Sierra Leone; Amudat and Bundibugyo, Uganda) may have resulted in
          systematic differences in local antimalarial efficacy compared to other regions of the
          country. Evidence suggests that malnourished children have an increased risk of treatment
          failure [<xref ref-type="bibr" rid="pmed-0050169-b008">8–10</xref>]. Organisations conducting studies in crisis-affected
          settings need to consider the generalisability of their data carefully in addition to the
          more general problem of extrapolating findings from individual sites to wider
        populations.</p>
      </sec>
      <sec id="s4b">
        <title>Planning and organisational strategy.</title>
        <p>MSF's contribution was not systematically planned but rather ad hoc, driven by its
          programmes. In retrospect, MSF's approach could have been more systematic, and more
          adherent to the standards of evidence-based medicine, in which randomised clinical trials
          are the primary tool by which inefficacious treatments are replaced once a more
          efficacious and equally safe alternative is identified. The approach shifted over time
          from measuring the efficacy of CQ and alternative potential partner drugs to combine with
          AS, to assuming that CQ was already inefficacious and focusing on head-on comparisons of
          different ACT combinations. MSF's strategy thus wavered between building an evidence base
          to argue against continued CQ use, trying to establish the baseline resistance of typical
          partner drugs, and a more pragmatic approach of directly investigating combinations.</p>
      </sec>
      <sec id="s4c">
        <title>Logistical and implementation challenges.</title>
        <p>Carrying out field research in some of the remote settings proved extremely challenging.
          For example, Caala, Angola was under military siege and affected by a humanitarian
          emergency during the study period. In Bundibugyo, Uganda, security constraints due to
          rebel incursions necessitated innovative solutions to trace patients not attending
          follow-up, including field visits by clinicians and laboratory staff. Shabunda, DRC and
          most Sudanese sites were accessible only by plane or on foot. Laboratory facilities were
          usually established from scratch, without electricity and with the threat of possible
          sources of contamination and degradation of slides and blood samples. While most study
          personnel were from the country itself, it was necessary to either recruit qualified
          professionals from other areas of the country, or re-train local staff who had been
          unemployed for years because of health system collapse. The vast majority had no prior
          experience in research. Research procedures had to be adapted to programmes hitherto
          dedicated solely to emergency health care provision. The greatest evidence gaps may well
          be in remote locations featuring the most difficult research conditions. Organisations
          must be prepared to be flexible, innovative, and resourceful. Investment in basic
          infrastructure, training, and human resources is essential.</p>
        <p>Follow-up and rescue treatment were also problematic. The WHO assessment protocol
          required investigators to withhold rescue treatment in case of asymptomatic parasite
          recurrence, which carries a high risk of avoidable morbidity [<xref ref-type="bibr" rid="pmed-0050169-b011">11</xref>]. Follow-up visits took place
          at one-week intervals, during which patients with known parasitaemia would remain without
          rescue treatment. On two occasions (two children treated respectively with AQ and CQ who
          were parasitaemic during follow-up and who did not come back for further visits), we
          believe this contributed to avoidable deaths from severe malaria. As a response, we
          instituted frequent home visits by field workers to detect any symptom progression.</p>
        <p>Partly due to concerns about security-related interruptions to enrolment, a proportion of
          studies in the first half of the period were single arm or used sequential allocation
          procedures. Unplanned decisions to stop enrolment due to very high treatment failure were
          occasionally taken, thus exposing investigators to the criticism of having contravened the
          protocol; later, randomisation was introduced as the standard, along with systematic early
          stopping rules.</p>
      </sec>
      <sec id="s4d">
        <title>Quality versus timeliness.</title>
        <p>Efforts were made to improve the quality of the studies, including establishment of
          routine laboratory quality control procedures (internal controls and review of slides by
          reference laboratories) and standard protocols and operating procedures for clinical and
          laboratory work. From 2003, follow-up was systematically extended to 28 days, and PCR
          genotyping analyses were always done to adjust failure rates for re-infections. This is
          broadly considered an appropriate method for assessing drug efficacy and therefore yielded
          realistic estimates for each site [<xref ref-type="bibr" rid="pmed-0050169-b012">12</xref>].</p>
        <p>However, these analyses required the involvement of partner institutions (usually
          academic laboratories in Europe). Due to the heavy workload of these laboratories, PCR
          genotyping sometimes yielded considerable delays in releasing final results. In situations
          where treatment failure was severe, this raised an ethical dilemma of balancing the
          release of final results with the need for action. A common approach was to release
          preliminary, unadjusted failure rates based on 14-day follow-up, especially when these
          already warranted an urgent change of the current first-line therapy. This however often
          led to confusion, especially when subsequent 28-day results overturned the initial
          impression that other cheap non-ACT regimens were still efficacious (particularly SP, for
          which failures tend to occur late). Furthermore, MSF field officers mediating between
          study investigators and local stakeholders did not always have the technical expertise to
          discuss genotyping adjustment. With more complex methods, the extra time involved in
          ensuring that data are accurate must be weighed against the urgency of action in each
          setting. However, our experience shows that in order to avoid confusion it is preferable
          to await final results, as long as the delay is acceptable (to be determined on a
          case-by-case basis).</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Ethical Issues</title>
      <p>These studies presented ethical dilemmas common to research in crisis-affected populations
          [<xref ref-type="bibr" rid="pmed-0050169-b013">13</xref>]. Local
        clinicians had strong anecdotal evidence of poor drug efficacy, but lack of scientific
        evidence hindered advocacy to review treatment policies. Communities were particularly
        vulnerable to the effects of antimalarial drug resistance since they had poor access to
        health care, no recourse to efficacious second-line treatments, and limited civil rights and
        governance structures within which to voice their patient perspective. Furthermore,
        patients’ or caregivers’ ability to decide whether to participate in the
        study was severely constrained: the study venue was often their sole health care option, and
        their familiarity with biomedical concepts may have been insufficient to properly consider
        the risks and benefits of participation. Adhering to the strict follow-up schedule was also
        challenging, potentially entailing days of missed work.</p>
      <p>In many countries there was no institutional review board (IRB), and protocols were
        approved by Ministry of Health directorates for research, as well as local health
        authorities. We considered that even in the absence of formal IRB review, generating
        evidence on antimalarial efficacy was essential to stimulate policy change. The assessment
        protocol was standardised and recommended by WHO; regimens were non-experimental; and
        patients’ risk of untoward outcomes was lower than in routine care due to the
        systematic follow-up and availability of second-line regimens in case of treatment failure.
        These considerations persuaded us that the harm–benefit ratio was favourable. This
        experience suggests that ethical risks of conducting research should always be weighed
        against the consequences of inaction. Measures to minimise risk include standardising
        protocols, ensuring locally appropriate, understandable consent procedures, developing
        alternative structures for ethics review, and involving the community.</p>
    </sec>
    <sec id="s6">
      <title>Future Research Challenges</title>
      <p>Recently, several players have become involved in antimalarial efficacy assessment, and
        there are global initiatives to co-ordinate studies [<xref ref-type="bibr" rid="pmed-0050169-b014">14</xref>]. Today's challenges are different: (1) to
        detect resistance to ACTs as early as possible, best done by combining molecular and in vivo
        studies, and defining strategic surveillance sites where resistance is more likely to arise
        de novo or be introduced from other regions; and (2) to demonstrate that new regimens (e.g.,
        dihydroartemisinin-piperaquine) are at least as efficacious as current first-line ACTs and
        carry additional benefits in terms of safety, cost, or feasibility: this would require
        non-inferiority rather than comparative trial designs [<xref ref-type="bibr" rid="pmed-0050169-b015">15</xref>].</p>
    </sec>
    <sec id="s7">
      <title>Conclusions</title>
      <p>Our analysis shows that research can be performed in difficult settings to a high enough
        standard to ensure publication and to be useful in policy change.</p>
      <p>MSF's work shows that nongovernmental organisations (NGOs) can provide extensive evidence
        on the efficacy of most antimalarial regimens. This evidence probably affected malaria
        treatment policy decisions, as suggested by the high number of countries where
        recommendations and decisions were the same. However, this conclusion has to be drawn with
        caution: factors leading to policy change are many and difficult to measure, as are reasons
        for adopting one regimen over another.</p>
      <p>As part of their mandate, medical NGOs should be prepared to fill gaps in evidence,
        including evaluating current tools to control tropical diseases in hard-to-reach
        populations, and demonstrating the effectiveness of alternatives. Dissemination of findings
        in peer-reviewed journals is crucial to bolster the validity of such research and inform
        international policy and advocacy. While operational research can successfully be undertaken
        by NGOs, national malaria control programmes, WHO, and other major international disease
        control partnerships hold the primary responsibility for initiating such studies. Had such
        institutions stimulated a systematic process of monitoring antimalarial efficacy from the
        onset of reports of drug resistance, change might have occurred earlier. Finally, it is
        important that complacency does not set in. Artemisinin resistance may well arise, and
        countries, international bodies, and NGOs need to prospectively monitor the situation to
        avoid history repeating itself.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Pascal Ringwald (Global Malaria Programme/WHO) for sharing the databases compiled
        by WHO and for helpful advice and comments. We thank all authors and partner institutions of
        the individual studies (some of which provided helpful comments), who unfortunately cannot
        all be listed in this paper. Thank you to Christa Hook for her important work as the
        Coordinator of the MSF Malaria Working Group. We are grateful to Elizabeth Ashley
        (Epicentre) and Rebecca Freeman Grais (Epicentre) for helpful comments on final versions of
        the manuscript. Thank you to Nick White (Wellcome Trust), François Nosten
        (Wellcome Trust), and Piero Olliaro (TDR-WHO) for their constant support during all these
        years.</p>
      <p><bold>List of principal investigators (or first author of paper/report) of individual
          studies</bold>: C. Bachy, M. Bonnet, P. Campbell, F. Checchi, E. Depoortere, X. de
        Radiguès, F. Grandesso, J. P. Guthmann, B. Janssens, S. Hamour, R. Hardwick, D.
        Legros, P. Piola, T. Prinsberg, G. Priotto, F. Smithuis, E. Stivanello, T. Swarthout, I. van
        den Broek.</p>
    </ack>
    <fn-group><fn fn-type="other">
        <p>The list of principal authors of individual studies is given at the end of the paper.</p>
      </fn></fn-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ACT</term>
          <def>
            <p>artemisinin-based combination therapy</p>
          </def>
        </def-item>
        <def-item>
          <term>AQ</term>
          <def>
            <p>amodiaquine</p>
          </def>
        </def-item>
        <def-item>
          <term>AS</term>
          <def>
            <p>artesunate</p>
          </def>
        </def-item>
        <def-item>
          <term>CQ</term>
          <def>
            <p>chloroquine</p>
          </def>
        </def-item>
        <def-item>
          <term>DRC</term>
          <def>
            <p>Democratic Republic of the Congo</p>
          </def>
        </def-item>
        <def-item>
          <term>MSF</term>
          <def>
            <p>Medecins Sans Frontieres</p>
          </def>
        </def-item>
        <def-item>
          <term>MQ</term>
          <def>
            <p>mefloquine</p>
          </def>
        </def-item>
        <def-item>
          <term>NGO</term>
          <def>
            <p>non-governmental organisation</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <named-content content-type="genus-species" xlink:type="simple">Pf</named-content>
          </term>
          <def>
            <p>
              <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content>
            </p>
          </def>
        </def-item>
        <def-item>
          <term>SP</term>
          <def>
            <p>sulfadoxine-pyrimethamine</p>
          </def>
        </def-item>
        <def-item>
          <term>WHO</term>
          <def>
            <p>World Health Organization</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0050169-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Trape</surname><given-names>JF</given-names></name></person-group>
          <year>2001</year>
          <article-title>The public health impact of chloroquine resistance in Africa.</article-title>
          <source>Am J Trop Med Hyg</source>
          <volume>64 </volume>
          <issue>1–2 Suppl</issue>
          <fpage>12</fpage>
          <lpage>17</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Zucker</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ruebush</surname><given-names>TK</given-names><suffix>II</suffix></name><name name-style="western"><surname>Obonyo</surname><given-names>C</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>J</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>C</given-names></name></person-group>
          <year>2003</year>
          <article-title>The mortality consequences of the continued use of chloroquine in Africa:
            Experience in Siaya, Western Kenya.</article-title>
          <source>Am J Trop Med Hyg</source>
          <volume>68</volume>
          <fpage>386</fpage>
          <lpage>390</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Nosten</surname><given-names>F</given-names></name><name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>WM</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K</given-names></name><etal/></person-group>
          <year>1999</year>
          <article-title>Averting a malaria disaster.</article-title>
          <source>Lancet</source>
          <volume>353</volume>
          <fpage>1965</fpage>
          <lpage>1967</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b004">
        <label>4</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>1996</year>
          <article-title>Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated
            falciparum malaria in areas with intense transmission.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/drugresistance/malaria/en/Assessment_malaria_96.pdf" xlink:type="simple">http://www.who.int/drugresistance/malaria/en/Assessment_malaria_96.pdf</ext-link>.
            Accessed 7 July 2008</comment>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b005">
        <label>5</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>2003</year>
          <article-title>Assessment and monitoring of antimalarial drug efficacy for the treatment
            of uncomplicated falciparum malaria.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/docs/ProtocolWHO.pdf" xlink:type="simple">http://www.who.int/malaria/docs/ProtocolWHO.pdf</ext-link>. Accessed 7 July
          2008</comment>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b006">
        <label>6</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>2005</year>
          <article-title>Susceptibility of <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> to antimalarial drugs.</article-title>
          <comment>Report on global monitoring, 1996–2004. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/rbm/Attachment/20041108/SusceptibilityPlasmodium_report.pdf" xlink:type="simple">http://www.who.int/malaria/rbm/Attachment/20041108/SusceptibilityPlasmodium_report.pdf</ext-link>.
            Accessed 7 July 2008</comment>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b007">
        <label>7</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">World Health Organization</collab>
          <year>2003</year>
          <article-title>Position of WHO's Roll Back Malaria Department on malaria treatment policy.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/treatmentguidelines.html" xlink:type="simple">http://www.who.int/malaria/treatmentguidelines.html</ext-link>. Accessed 7 July
          2008</comment>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Hess</surname><given-names>FI</given-names></name><name name-style="western"><surname>Iannuzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Leafasia</surname><given-names>J</given-names></name><name name-style="western"><surname>Cowdrey</surname><given-names>D</given-names></name><name name-style="western"><surname>Nothdurft</surname><given-names>HD</given-names></name><etal/></person-group>
          <year>1996</year>
          <article-title>Risk factors of chloroquine resistance in <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content> malaria.</article-title>
          <source>Acta Trop</source>
          <volume>61</volume>
          <fpage>293</fpage>
          <lpage>306</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Hamel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Holtz</surname><given-names>T</given-names></name><name name-style="western"><surname>Mkandala</surname><given-names>C</given-names></name><name name-style="western"><surname>Kaimila</surname><given-names>N</given-names></name><name name-style="western"><surname>Chizani</surname><given-names>N</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Efficacy of trimethoprim-sulfamethoxazole compared with
            sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria
            in children with integrated management of childhood illness dual classifications of
            malaria and pneumonia.</article-title>
          <source>Am J Trop Med Hyg</source>
          <volume>73</volume>
          <fpage>609</fpage>
          <lpage>615</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b010">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Olanrewaju</surname><given-names>WI</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AW</given-names></name></person-group>
          <year>2001</year>
          <article-title>Chloroquine-resistant <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content> malaria in Ilorin, Nigeria: Prevalence and risk
            factors for treatment failure.</article-title>
          <source>Afr J Med Med Sci</source>
          <volume>30</volume>
          <fpage>165</fpage>
          <lpage>169</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b011">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Olliaro</surname><given-names>P</given-names></name><name name-style="western"><surname>Pinoges</surname><given-names>L</given-names></name><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Vaillant</surname><given-names>M</given-names></name><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name></person-group>
          <year>2008</year>
          <article-title>Risk associated with asymptomatic parasitaemia occurring post-antimalarial
            treatment.</article-title>
          <source>Trop Med Int Health</source>
          <volume>13</volume>
          <fpage>83</fpage>
          <lpage>90</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b012">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pinoges</surname><given-names>L</given-names></name><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cousens</surname><given-names>S</given-names></name><name name-style="western"><surname>Balkan</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Methodological issues in the assessment of antimalarial drug treatment:
            Analysis of 13 studies in eight African countries from 2001 to 2004.</article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>50</volume>
          <fpage>3734</fpage>
          <lpage>3739</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b013">
        <label>13</label>
        <element-citation publication-type="other" xlink:type="simple">
          <collab xlink:type="simple">Committee on Population, National Research Council</collab>
          <year>2002</year>
          <article-title>Research ethics in complex humanitarian emergencies: Summary of a workshop.
            National Academy Press.</article-title>
          <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://books.nap.edu/catalog.php?record_id=10481" xlink:type="simple">http://books.nap.edu/catalog.php?record_id=10481</ext-link>. Accessed 7 July
          2008</comment>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b014">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Price</surname><given-names>R</given-names></name><name name-style="western"><surname>Dorsey</surname><given-names>G</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>E</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>K</given-names></name><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><etal/></person-group>
          <year>2007</year>
          <article-title>World Antimalarial Resistance Network I: Clinical efficacy of antimalarial
            drugs.</article-title>
          <source>Malar J</source>
          <volume>6</volume>
          <fpage>119</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b015">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Stepniewska</surname><given-names>K</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
          <year>2006</year>
          <article-title>Some considerations in the design and interpretation of antimalarial drug
            trials in uncomplicated falciparum malaria.</article-title>
          <source>Malar J</source>
          <volume>5</volume>
          <fpage>127</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b016">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Smithuis</surname><given-names>F</given-names></name><name name-style="western"><surname>Shahmanesh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>MK</given-names></name><name name-style="western"><surname>Savran</surname><given-names>O</given-names></name><name name-style="western"><surname>Lwin</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and
            mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North
            Myanmar.</article-title>
          <source>Trop Med Int Health</source>
          <volume>9</volume>
          <fpage>1184</fpage>
          <lpage>1190</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b017">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kasparian</surname><given-names>S</given-names></name><name name-style="western"><surname>Phetsouvanh</surname><given-names>R</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>The efficacy of chloroquine for the treatment of acute, uncomplicated,
              <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content>
            malaria in Laos.</article-title>
          <source>Ann Trop Med Parasitol</source>
          <volume>96</volume>
          <fpage>553</fpage>
          <lpage>557</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b018">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Priotto</surname><given-names>G</given-names></name><name name-style="western"><surname>Kabakyenga</surname><given-names>J</given-names></name><name name-style="western"><surname>Pinoges</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>T</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of
            uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
            falciparum</named-content> malaria in Uganda: A randomized, double-blind,
            placebo-controlled trial.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>97</volume>
          <fpage>325</fpage>
          <lpage>330</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b019">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Stivanello</surname><given-names>E</given-names></name><name name-style="western"><surname>Cavailler</surname><given-names>P</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>F</given-names></name><name name-style="western"><surname>Omar</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kariuki</surname><given-names>D</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Efficacy of chloroquine, sulphadoxine-pyrimethamine and amodiaquine for
            treatment of uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> malaria in Kajo Keji county, Sudan.</article-title>
          <source>Trop Med Int Health</source>
          <volume>9</volume>
          <fpage>975</fpage>
          <lpage>980</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b020">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Smithuis</surname><given-names>F</given-names></name><name name-style="western"><surname>van der Broek</surname><given-names>I</given-names></name><name name-style="western"><surname>Katterman</surname><given-names>N</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>MK</given-names></name><name name-style="western"><surname>Brockman</surname><given-names>A</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Optimising operational use of artesunate-mefloquine: A randomised
            comparison of four treatment regimens.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>98</volume>
          <fpage>182</fpage>
          <lpage>192</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b021">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Campbell</surname><given-names>P</given-names></name><name name-style="western"><surname>Baruah</surname><given-names>S</given-names></name><name name-style="western"><surname>Narain</surname><given-names>K</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>CC</given-names></name></person-group>
          <year>2006</year>
          <article-title>A randomized trial comparing the efficacy of four treatment regimens for
            uncomplicated falciparum malaria in Assam state, India.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>100</volume>
          <fpage>108</fpage>
          <lpage>118</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b022">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>van den Broek</surname><given-names>IV</given-names></name><name name-style="western"><surname>van der Wardt</surname><given-names>S</given-names></name><name name-style="western"><surname>Talukder</surname><given-names>L</given-names></name><name name-style="western"><surname>Chakma</surname><given-names>S</given-names></name><name name-style="western"><surname>Brockman</surname><given-names>A</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Drug resistance in <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> from the Chittagong Hill Tracts, Bangladesh.</article-title>
          <source>Trop Med Int Health</source>
          <volume>9</volume>
          <fpage>680</fpage>
          <lpage>687</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b023">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Durand</surname><given-names>R</given-names></name><name name-style="western"><surname>Balkan</surname><given-names>S</given-names></name><name name-style="western"><surname>Vonhm</surname><given-names>BT</given-names></name><name name-style="western"><surname>Kollie</surname><given-names>JZ</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>High <named-content content-type="genus-species" xlink:type="simple">Plasmodium
            falciparum</named-content> resistance to chloroquine and sulfadoxine-pyrimethamine in
            Harper, Liberia: Results in vivo and analysis of point mutations.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>96</volume>
          <fpage>664</fpage>
          <lpage>669</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b024">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Balkan</surname><given-names>S</given-names></name><name name-style="western"><surname>Vonhm</surname><given-names>BT</given-names></name><name name-style="western"><surname>Massaquoi</surname><given-names>M</given-names></name><name name-style="western"><surname>Biberson</surname><given-names>P</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Efficacy of amodiaquine for uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content> malaria in Harper,
            Liberia.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>96</volume>
          <fpage>670</fpage>
          <lpage>673</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b025">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Depoortere</surname><given-names>E</given-names></name><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pressé</surname><given-names>J</given-names></name><name name-style="western"><surname>Sipilanyambe</surname><given-names>N</given-names></name><name name-style="western"><surname>Nkandu</surname><given-names>E</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine
            and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria
            in a refugee settlement in Zambia.</article-title>
          <source>Trop Med Int Health</source>
          <volume>10</volume>
          <fpage>139</fpage>
          <lpage>145</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b026">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Piola</surname><given-names>P</given-names></name><name name-style="western"><surname>Kosack</surname><given-names>C</given-names></name><name name-style="western"><surname>Ardizzoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Klarkowski</surname><given-names>D</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a
            combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda.</article-title>
          <source>Trop Med Int Health</source>
          <volume>9</volume>
          <fpage>445</fpage>
          <lpage>450</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b027">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Grandesso</surname><given-names>F</given-names></name><name name-style="western"><surname>Bachy</surname><given-names>C</given-names></name><name name-style="western"><surname>Donam</surname><given-names>I</given-names></name><name name-style="western"><surname>Ntambi</surname><given-names>J</given-names></name><name name-style="western"><surname>Habimana</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for
            treatment of uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> malaria among children under five in Bongor and Koumra,
            Chad.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>100</volume>
          <fpage>419</fpage>
          <lpage>426</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b028">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>van den Broek</surname><given-names>IV</given-names></name><name name-style="western"><surname>Maung</surname><given-names>UA</given-names></name><name name-style="western"><surname>Peters</surname><given-names>A</given-names></name><name name-style="western"><surname>Liem</surname><given-names>L</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>M</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Efficacy of chloroquine + sulfadoxine–pyrimethamine,
            mefloquine + artesunate and artemether + lumefantrine combination
            therapies to treat <named-content content-type="genus-species" xlink:type="simple">Plasmodium
            falciparum</named-content> malaria in the Chittagong Hill Tracts, Bangladesh.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>99</volume>
          <fpage>727</fpage>
          <lpage>735</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b029">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Hamour</surname><given-names>S</given-names></name><name name-style="western"><surname>Melaku</surname><given-names>Y</given-names></name><name name-style="western"><surname>Keus</surname><given-names>K</given-names></name><name name-style="western"><surname>Wambugu</surname><given-names>J</given-names></name><name name-style="western"><surname>Atkin</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Malaria in the Nuba Mountains of Sudan: Baseline genotypic resistance and
            efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus
            amodiaquine combinations.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>99</volume>
          <fpage>548</fpage>
          <lpage>554</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b030">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Roddy</surname><given-names>P</given-names></name><name name-style="western"><surname>Kamara</surname><given-names>S</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Morineau</surname><given-names>G</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Evidence basis for antimalarial policy change in Sierra Leone: Five in vivo
            efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine.</article-title>
          <source>Trop Med Int Health</source>
          <volume>10</volume>
          <fpage>146</fpage>
          <lpage>153</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b031">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>van den Broek</surname><given-names>I</given-names></name><name name-style="western"><surname>Amsalu</surname><given-names>R</given-names></name><name name-style="western"><surname>Balasegaram</surname><given-names>M</given-names></name><name name-style="western"><surname>Hepple</surname><given-names>P</given-names></name><name name-style="western"><surname>Alemu</surname><given-names>E</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Efficacy of two artemisinin combination therapies for uncomplicated
            falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan.</article-title>
          <source>Malar J</source>
          <volume>4</volume>
          <fpage>14</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b032">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ampuero</surname><given-names>J</given-names></name><name name-style="western"><surname>Fortes</surname><given-names>F</given-names></name><name name-style="western"><surname>van Overmeir</surname><given-names>C</given-names></name><name name-style="western"><surname>Gaboulaud</surname><given-names>V</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Antimalarial efficacy of chloroquine, amodiaquine,
            sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and
            sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central
            Angola.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>99</volume>
          <fpage>485</fpage>
          <lpage>492</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b033">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Janssens</surname><given-names>B</given-names></name><name name-style="western"><surname>van Herp</surname><given-names>M</given-names></name><name name-style="western"><surname>Goubert</surname><given-names>L</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S</given-names></name><name name-style="western"><surname>Uong</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2007</year>
          <article-title>A randomized open study to assess the efficacy and tolerability of
            dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in
            Cambodia.</article-title>
          <source>Trop Med Int Health</source>
          <volume>12</volume>
          <fpage>251</fpage>
          <lpage>259</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b034">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Bonnet</surname><given-names>M</given-names></name><name name-style="western"><surname>Roper</surname><given-names>C</given-names></name><name name-style="western"><surname>Félix</surname><given-names>M</given-names></name><name name-style="western"><surname>Coulibaly</surname><given-names>L</given-names></name><name name-style="western"><surname>Kankolongo</surname><given-names>GM</given-names></name><etal/></person-group>
          <year>2007</year>
          <article-title>Efficacy of antimalarial treatment in Guinea: In vivo study of two
            artemisinin combination therapies in Dabola and molecular markers of resistance to
            sulphadoxine-pyrimethamine in N’Zérékoré.</article-title>
          <source>Malar J</source>
          <volume>6</volume>
          <fpage>54</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b035">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Swarthout</surname><given-names>TD</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>IV</given-names></name><name name-style="western"><surname>Kayembe</surname><given-names>G</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>J</given-names></name><name name-style="western"><surname>Pota</surname><given-names>H</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Artesunate + amodiaquine and artesunate +
            sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic
            of Congo: A clinical trial with determination of sulphadoxine and
            pyrimethamine-resistant haplotypes.</article-title>
          <source>Trop Med Int Health</source>
          <volume>11</volume>
          <fpage>1503</fpage>
          <lpage>1511</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b036">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>van den Broek</surname><given-names>I</given-names></name><name name-style="western"><surname>Kitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Al Attas</surname><given-names>S</given-names></name><name name-style="western"><surname>Libama</surname><given-names>F</given-names></name><name name-style="western"><surname>Balasegaram</surname><given-names>M</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Efficacy of three artemisinin combination therapies for the treatment of
            uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
            falciparum</named-content> malaria in the Republic of Congo.</article-title>
          <source>Malar J</source>
          <volume>5</volume>
          <fpage>113</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b037">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Piola</surname><given-names>P</given-names></name><name name-style="western"><surname>Fogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Bajunirwe</surname><given-names>F</given-names></name><name name-style="western"><surname>Biraro</surname><given-names>S</given-names></name><name name-style="western"><surname>Grandesso</surname><given-names>F</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Supervised versus unsupervised intake of six-dose artemether-lumefantrine
            for treatment of acute, uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium falciparum</named-content> malaria in Mbarara, Uganda: A randomised trial.</article-title>
          <source>Lancet</source>
          <volume>365</volume>
          <fpage>1467</fpage>
          <lpage>1473</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b038">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Cohuet</surname><given-names>S</given-names></name><name name-style="western"><surname>Rigutto</surname><given-names>C</given-names></name><name name-style="western"><surname>Fortes</surname><given-names>F</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>N</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>High efficacy of two artemisinin-based combinations (artesunate +
            amodiaquine and artemether + lumefantrine) in Caala, Central Angola.</article-title>
          <source>Am J Trop Med Hyg</source>
          <volume>75</volume>
          <fpage>143</fpage>
          <lpage>145</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b039">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Grandesso</surname><given-names>F</given-names></name><name name-style="western"><surname>Hagerman</surname><given-names>A</given-names></name><name name-style="western"><surname>Kamara</surname><given-names>S</given-names></name><name name-style="western"><surname>Lam</surname><given-names>E</given-names></name><name name-style="western"><surname>Checchi</surname><given-names>F</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Low efficacy of the combination artesunate plus amodiaquine for
            uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone.</article-title>
          <source>Trop Med Int Health</source>
          <volume>11</volume>
          <fpage>1017</fpage>
          <lpage>1021</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b040">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>de Radiguès</surname><given-names>X</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>KI</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>M</given-names></name><name name-style="western"><surname>Ngwakum</surname><given-names>PA</given-names></name><name name-style="western"><surname>Maiga</surname><given-names>H</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Efficacy of chloroquine and sulfadoxine/ pyrimethamine for the treatment of
            uncomplicated falciparum malaria in Koumantou, Mali.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>100</volume>
          <fpage>1013</fpage>
          <lpage>1018</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b041">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Smithuis</surname><given-names>F</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>MK</given-names></name><name name-style="western"><surname>Phe</surname><given-names>O</given-names></name><name name-style="western"><surname>Aye</surname><given-names>KZ</given-names></name><name name-style="western"><surname>Htet</surname><given-names>L</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Efficacy and effectiveness of dihydroartemisinin-piperaquine versus
            artesunate-mefloquine in falciparum malaria: An open-label randomised comparison.</article-title>
          <source>Lancet</source>
          <volume>367</volume>
          <fpage>2075</fpage>
          <lpage>2085</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b042">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Legros</surname><given-names>D</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name><name name-style="western"><surname>Houpikian</surname><given-names>P</given-names></name><name name-style="western"><surname>Makanga</surname><given-names>M</given-names></name><name name-style="western"><surname>Kabakyenga</surname><given-names>JK</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children
            under five from south-western Uganda with uncomplicated falciparum malaria.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>96</volume>
          <fpage>199</fpage>
          <lpage>201</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b043">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>Kazadi</surname><given-names>WM</given-names></name><name name-style="western"><surname>Vong</surname><given-names>S</given-names></name><name name-style="western"><surname>Makina</surname><given-names>BN</given-names></name><name name-style="western"><surname>Mantshumba</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kabuya</surname><given-names>W</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for
            treatment of uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> malaria in the Democratic Republic of Congo.</article-title>
          <source>Trop Med Int Health</source>
          <volume>8</volume>
          <fpage>868</fpage>
          <lpage>875</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0050169-b044">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group><name name-style="western"><surname>van den Broek</surname><given-names>IV</given-names></name><name name-style="western"><surname>Gatkoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Lowoko</surname><given-names>B</given-names></name><name name-style="western"><surname>Nzila</surname><given-names>A</given-names></name><name name-style="western"><surname>Ochong</surname><given-names>E</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the
            treatment of uncomplicated <named-content content-type="genus-species" xlink:type="simple">Plasmodium
              falciparum</named-content> malaria in Upper Nile, south Sudan.</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <volume>97</volume>
          <fpage>229</fpage>
          <lpage>235</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>